The search for novel therapeutic strategies in the treatment of recurrent glioblastoma multiforme

Expert Review of Anticancer Therapy

Volumn 14, Issue 8, 2014, Pages 955-964

  Bambury, Richard M ^a   Morris, Patrick G ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b BEAUMONT HOSPITAL   (Ireland)

Author keywords

antiangiogenic; glioblastoma; immunotherapy; targeted therapy; temozolomide

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BIOLOGICAL MARKER; BUPARLISIB; CARMUSTINE; CETUXIMAB; CILENGITIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; GEFITINIB; LOMUSTINE; MAMMALIAN TARGET OF RAPAMYCIN; ONCOLYTIC PARVOVIRUS; PAZOPANIB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RAF PROTEIN; RAMUCIRUMAB; RAPAMYCIN; RETINOBLASTOMA PROTEIN; RINDOPEPIMUT; SUNITINIB; TEMOZOLOMIDE; TIVOZANIB; TREBANANIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN A; VB 111; TUMOR MARKER;

BLEEDING; BLOOD BRAIN BARRIER; BRAIN HEMORRHAGE; BRAIN METASTASIS; BRAIN SURGERY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RESEARCH; CARCINOGENESIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EGFR GENE; ELECTROMAGNETIC FIELD; EPIGENETICS; GENETICS; GLIOBLASTOMA; HEALTH CARE QUALITY; HUMAN; HYPERTENSION; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NONHUMAN; ONCOLYTIC VIROTHERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PIK3CA GENE; PIK3R1 GENE; PRACTICE GUIDELINE; PROGRESSION FREE SURVIVAL; PROTEINURIA; PTEN GENE; REVIEW; SIGNAL TRANSDUCTION; STEREOTACTIC TREATMENT; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR TREATING FIELDS THERAPY; VEGFA GENE; ANIMAL; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; DISEASE COURSE; IMMUNOTHERAPY; METABOLISM; PATHOLOGY; PROCEDURES; SURVIVAL RATE; TUMOR RECURRENCE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; DISEASE PROGRESSION; GLIOBLASTOMA; HUMANS; IMMUNOTHERAPY; NEOPLASM RECURRENCE, LOCAL; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84905013281     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2014.916214     Document Type: Review

References (93)

1. Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro-oncol 2012;14(Suppl 5): V1-49
2. Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: A clinical review. JAMA 2013;310(17):1842-50
3. Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: Clinical article. J Neurosurg 2012;117(6):1032-8
4. Combs SE, Thilmann C, Edler L, et al. Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: Long-term results in 172 patients treated in a single institution. J Clin Oncol 2005;23(34): 8863-9
5. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27(28):4733-40
6. Perry JR, Belanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol 2010;28(12):2051-7
7. Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 2010;28(7):1168-74
8. Cancer Genome Atlas Research N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455(7216):1061-8
9. Brennan CW, Verhaak RG, McKenna A, et al. The somatic genomic landscape of glioblastoma. Cell 2013;155(2):462-77
10. Lamszus K, Ulbricht U, Matschke J, et al. Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A. Clin Cancer Res 2003;9(4):1399-405
11. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009;27(5):740-5
12. Cloughesy T, Vredenburgh JJ, Day B, et al. for the BRAIN Investigators. Updated safety and survival of patients with relapsed glioblastoma treated with bevacizumab in the BRAIN study. ASCO Meeting Abstracts 2010;28:15 Suppl; abstr 2008
13. Gilbert MR, Dignam J, Won M, et al. RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM). ASCO Meeting Abstracts 2013; 31(18 Suppl):1
14. Cloughsey T, Wick W, Mason W, et al. Phase III trial of bevacizumab added to standard radiotherapy and temozolomide for newly diagnosed glioblastoma: Final progression-free survival and preliminary overall survival results from avaglio (PL02.002). Neurology 2013; 80(Meeting Abstracts 1):PL02.002
15. A double-blind, placebo-controlled, randomized, Phase IIIb trial evaluating the efficacy and safety of standard of care (SOC) +/-continuous bevacizumab treatment following progression of disease (PD) in patients with glioblastoma (GBM) after first (1st)-line treatment with radiotherapy, temozolomide and bevacizumab-TAMIGA. 2014
16. Socinski MA, Langer CJ, Huang JE, et al. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol 2009;27(31): 5255-61
17. Hegde PS, Jubb AM, Chen D, et al. Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab. Clin Cancer Res 2013;19(4):929-37
18. Loupakis F, Ruzzo A, Salvatore L, et al. Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. BMC Cancer 2011;11:247
19. Lambrechts D, Claes B, Delmar P, et al. VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: An analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol 2012;13(7):724-33
20. Van Cutsem E, de Haas S, Kang YK, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol 2012;30(17): 2119-27
21. Lombardi G, Zustovich F, Farina P, et al. Hypertension as a biomarker in patients with recurrent glioblastoma treated with antiangiogenic drugs: A single-center experience and a critical review of the literature. Anticancer Drugs 2013;24(1): 90-7
22. Iwamoto FM, Lamborn KR, Robins HI, et al. Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro-oncol 2010;12(8):855-61
23. Kreisl TN, Smith P, Sul J, et al. Continuous daily sunitinib for recurrent glioblastoma. J Neurooncol 2013;111(1): 41-8
24. Pan E, Yu D, Yue B, et al. A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma. J Neurooncol 2012;110(1):111-18
25. Hassler MR, Ackerl M, Flechl B, et al. Sorafenib for patients with pretreated recurrent or progressive high-grade glioma: A retrospective, single-institution study. Anticancer Drugs 2014. [Epub ahead of print]
26. Bambury RM, Morris PG. Novel investigational approaches for inhibiting angiogenesis in recurrent glioblastoma anti-cancer drugs. 2014;In press
27. Zustovich F, Landi L, Lombardi G, et al. Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: A phase II study. Anticancer Res 2013;33(8):3487-94
28. Nabors LB, Mikkelsen T, Hegi ME, et al. A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). Cancer 2012; 118(22):5601-7
29. Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma and methylated O6-methylguanine-DNA methyltransferase (MGMT) gene promoter: Key results of the multicenter, randomized, open-label, controlled, phase III CENTRIC study. ASCO Meeting Abstracts 2013; 31(18 Suppl):LBA2009
30. Reardon DA, Fink KL, Mikkelsen T, et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 2008;26(34):5610-17
31. ClinicalTrials.gov. Amgen 386 for recurrent glioblastoma. 2013. Available from: Http://clinicaltrials.gov/ct2/show/NCT01290263
32. ClinicalTrials.gov. Tivozanib for recurrent glioblastoma. 2013. Available from: Http://clinicaltrials.gov/show/NCT01846871
33. ClinicalTrials.gov. Single-arm open-label multicenter study of VB-111 in patients with recurrent glioblastoma multiforme. 2013. Available from: Http://clinicaltrials. gov/show/NCT01260506
34. ClinicalTrials.gov. Ramucirumab or anti-PDGFR alpha monoclonal antibody IMC-3G3 in treating patients with recurrent glioblastoma multiforme. 2014. Available from: Http://clinicaltrials.gov/show/NCT00895180
35. Huang PH, Xu AM, White FM. Oncogenic EGFR signaling networks in glioma. Sci Signal 2009;2(87):re6
36. van den Bent MJ, Brandes AA, Rampling R, et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol 2009; 27(8):1268-74
37. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13(3): 239-46
38. Hegi ME, Diserens AC, Bady P, et al. Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib-A phase II trial. Mol Cancer Ther 2011;10(6): 1102-12
39. ClinicalTrials.gov. EGFR inhibition using high dose administration of erlotinib weekly for recurrent malignant gliomas with EGFR variant III mutation. 2013. Available from: Http://clinicaltrials.gov/show/NCT01257594
40. Neyns B, Sadones J, Joosens E, et al. Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. Ann Oncol 2009;20(9):1596-603
41. Super-selective intraarterial cerebral infusion of cetuximab for the treatment of recurrent glioblastoma multiforme and anaplastic astrocytoma. 2013. Available from: Http://clinicaltrials.gov/show/NCT01238237
42. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372(9637):449-56
43. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366(6):520-9
44. Galanis E, Buckner JC, Maurer MJ, et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A North Central Cancer Treatment Group Study. J Clin Oncol 2005;23(23):5294-304
45. Kreisl TN, Lassman AB, Mischel PS, et al. A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM). J Neurooncol 2009;92(1):99-105
46. Koul D, Fu J, Shen R, et al. Antitumor activity of NVP-BKM120-A selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells. Clin Cancer Res 2012;18(1):184-95
47. ClinicalTrials.gov. Phase II study of BKM120 for subjects with recurrent glioblastoma. 2013. Available from: Http://clinicaltrials.gov/ct2/show/ NCT01339052
48. ClinicalTrials.gov. Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme. 2013. Available from: Http://clinicaltrials.gov/show/NCT01349660
49. Schlehofer B, Blettner M, Preston-Martin S, et al. Role of medical history in brain tumour development. Results from the international adult brain tumour study. Int J Cancer 1999;82(2):155-60
50. Lohr J, Ratliff T, Huppertz A, et al. Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-beta. Clin Cancer Res 2011;17(13):4296-308
51. Bambury RM, Teo MY, Power DG, et al. The association of pre-treatment neutrophil to lymphocyte ratio with overall survival in patients with glioblastoma multiforme. J Neurooncol 2013;114(1):149-54
52. Alexiou GA, Vartholomatos E, Voulgaris S. Prognostic value of neutrophil-to-lymphocyte ratio in patients with glioblastoma. J Neurooncol 2013; 115(3):521-2
53. Buckner JC, Schomberg PJ, McGinnis WL, et al. A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma. Cancer 2001;92(2): 420-33
54. Sampson JH, Heimberger AB, Archer GE, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 2010;28(31): 4722-9
55. ClinicalTrials.gov. Phase III study of rindopepimut/GM-CSF in Patients with newly diagnosed glioblastoma (ACT IV). Available from: Http:// clinicaltrials.gov/ct2/show/NCT01480479
56. ClinicalTrials.gov. A study of rindopepimut/GM-CSF in Patients with relapsed EGFRvIII-positive glioblastoma (ReACT). 2013. Available from: Http://clinicaltrials. gov/show/NCT01498328
57. Ning J, Wakimoto H, Rabkin SD. Immunovirotherapy for glioblastoma. Cell Cycle 2014;13(2):175-6
58. Toda M, Rabkin SD, Kojima H, Martuza RL. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum Gene Ther 1999;10(3):385-93
59. ClinicalTrials.gov. A Study of a Retroviral replicating vector administered to subjects with recurrent malignant glioma. 2014. Available from: Http://clinicaltrials.gov/show/NCT01156584
60. ClinicalTrials.gov. Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme. (ParvOryx01). 2014. Available from: Http://clinicaltrials.gov/show/NCT01301430
61. Liu Y, Carlsson R, Ambjorn M, et al. PD-L1 expression by neurons nearby tumors indicates better prognosis in glioblastoma patients. J Neurosci 2013; 33(35):14231-45
62. Zeng J, See AP, Phallen J, et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys 2013;86(2):343-9
63. ClinicalTrials.gov. Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma and Relapsed Glioblastoma Multiforme. 2013. Available from: Http://clinicaltrials.gov/show/NCT01952769
64. ClinicalTrials.gov. A Randomized Study of Nivolumab or Nivolumab Combined With Ipilimumab Versus Bevacizumab in Adult Subjects With Recurrent Glioblastoma. 2014. Available from: Http://clinicaltrials. gov/show/NCT02017717
65. Kirson ED, Gurvich Z, Schneiderman R, et al. Disruption of cancer cell replication by alternating electric fields. Cancer Res 2004;64(9):3288-95
66. Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality. Eur J Cancer 2012; 48(14):2192-202
67. US FDA. NovoTTF-100A system-P100034. 2011.Available from: Www.fda. gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/ MedicalDevicesAdvisoryCommittee/NeurologicalDevicesPanel/UCM247168.pdf
68. ClinicalTrials.gov. Effect of novoTTF-100A together with temozolomide in newly diagnosed glioblastoma multiforme (GBM). 2013. Available from: Http://clinicaltrials.gov/ct2/show/NCT00916409
69. ClinicalTrials.gov. Safety Feasibility and Effect of NovoTTF-100L Together With Gemcitabine for Front-line Therapy of Advanced Pancreatic Adenocarcinoma. 2013. Available from: Http://clinicaltrials. gov/ct2/show/NCT01971281
70. ClinicalTrials.gov. NovoTTF-100L in combination with pemetrexed (alimta-) for advanced non-small cell lung cancer. 2013. Available from: Http://clinicaltrials.gov/show/NCT00749346
71. Tuettenberg J, Seiz M, Debatin KM, et al. Pharmacokinetics, pharmacodynamics, safety and tolerability of APG101, a CD95-Fc fusion protein, in healthy volunteers and two glioma patients. Int Immunopharmacol 2012;13(1):93-100
72. Wick W, Debus J, Bendszus M, et al. A phase II, randomized, open-label, multi-center study of weekly APG101 + reirradiation versus reirradiation in the treatment of patients with recurrent glioblastoma [abstract 3304]. In: The European Cancer Congress 2013; Amsterdam, Netherlands; 2013
73. Kim JE, Patel M, Ruzevick J, et al. STAT3 Activation in glioblastoma: Biochemical and therapeutic implications. Cancers (Basel) 2014;6(1):376-95
74. Yu CL, Meyer DJ, Campbell GS, et al. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 1995; 269(5220):81-3
75. Garcia R, Bowman TL, Niu G, et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 2001;20(20): 2499-513
76. Bowman T, Broome MA, Sinibaldi D, et al. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc Natl Acad Sci U S A 2001;98(13):7319-24
77. Carro MS, Lim WK, Alvarez MJ, et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature 2010;463(7279):318-25
78. See AP, Han JE, Phallen J, et al. The role of STAT3 activation in modulating the immune microenvironment of GBM. J Neurooncol 2012;110(3):359-68
79. Wei J, Wu A, Kong LY, et al. Hypoxia potentiates glioma-mediated immunosuppression. PLoS One 2011;6(1): E16195
80. Lo HW, Cao X, Zhu H, Ali-Osman F. Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators. Clin Cancer Res 2008;14(19): 6042-54
81. Mizoguchi M, Betensky RA, Batchelor TT, et al. Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: Correlation with EGFR status, tumor grade, and survival. J Neuropathol Exp Neurol 2006;65(12):1181-8
82. Ashizawa T, Miyata H, Iizuka A, et al. Effect of the STAT3 inhibitor STX-0119 on the proliferation of cancer stem-like cells derived from recurrent glioblastoma. Int J Oncol 2013;43(1): 219-27
83. Fuh B, Sobo M, Cen L, et al. LLL-3 inhibits STAT3 activity, suppresses glioblastoma cell growth and prolongs survival in a mouse glioblastoma model. Br J Cancer 2009;100(1):106-12
84. Elisei R, Schlumberger MJ, Muller SP, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 2013;31(29): 3639-46
85. Wen PY, Prados M, Schiff D, et al. Phase II study of XL184 (BMS 907351), an inhibitor of MET, VEGFR2, and RET, in patients (pts) with progressive glioblastoma (GB). ASCO Meeting Abstracts 2010; 28(15 Suppl):2006
86. Johnson N, Shapiro GI. Cyclin-dependent kinase 4/6 inhibition in cancer therapy. Cell Cycle 2012;11(21):3913
87. Finn RS, Crown JP, Lang I, et al. Results of a randomized phase 2 study of PD 0332991, a cyclin dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2-advanced breast cancer (BC) [abstract S1-6]. In: San Antonio Breast Cancer Symposium 2012; San Antonio, Texas, USA; 2012
88. ClinicalTrials.gov. A study of PD 0332991 in patients with recurrent rb positive glioblastoma. 2014. Available from: Http://clinicaltrials.gov/show/ NCT01227434
89. Dean JL, McClendon AK, Hickey TE, et al. Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. Cell Cycle 2012;11(14):2756-61
90. ClinicalTrials.gov. A study of onartuzumab (MetMAb) in combination with bevacizumab compared to bevacizumab alone or onartuzumab monotherapy in patients with recurrent glioblastoma. 2013. Available from: Http://clinicaltrials.gov/ show/NCT01632228
91. Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol 2013;31(26): 3212-18
92. Prados MD, Lamborn K, Yung WK, et al. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study. Neuro-oncol 2006;8(2): 189-93
93. Hutterer M, Nowosielski M, Haybaeck J, et al. A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07). Neuro-oncol 2014;16(1):92-102